FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207967> ?p ?o ?g. }

• W4387207967 endingPage "e315" @default.
• W4387207967 startingPage "e314" @default.
• W4387207967 abstract "Esophageal cancer had accounted for the sixth highest incidence and the fourth highest death rate in China. The predominant histological subtype is esophageal squamous cell carcinoma (ESCC). At initial diagnosis, more than half of patients with ESCC are unfit for surgery. An accepted alternative to surgery is concurrent chemoradiotherapy (cCRT); however, many patients experience local recurrence or distant metastasis after cCRT. Therefore, innovative therapies are needed. Sintilimab is a fully human IgG4 monoclonal antibody, exhibiting the highest affinity for human PD-1 and a lower off-rate, the PD-1 receptor occupancy of sintilimab on circulating T cells is superior. In previous studies, sintilimab, alone and in combination with chemotherapy, was generally well tolerated and had antitumor activity in patients with advanced ESCC.This prospective, single-arm study (NCT04602013) is designed to explore the efficacy of Sintilimab in combination with cCRT. Eligible patients have histologically confirmed localized ESCC for whom cCRT is suitable and surgery is unsuitable/ declined; patients couldn't have received prior chemoradiotherapy. Approximately 53 Chinese patients from 5 centers will be to receive sintilimab (body weight <60kg: 3mg/kg IV Q3W; body weight ≥60kg: 200mg IV Q3W) in combination with cisplatin (25 mg/m2 IV on Days 1-3 of each 3-week cycle) plus paclitaxel for injection (albumin bound) (180 mg/m2). and radiotherapy at a total dose of 60Gy. Duration of treatment will be up to 12 months for sintilimab, including two cycles for concurrent administration of chemotherapy and radiotherapy. Progression-free survival (PFS), assessed by a Blinded Independent Review Committee per RECIST v1.1, is the primary endpoint of the study. Secondary efficacy endpoints include overall response rate, duration of response, and overall survival. Incidence and severity of adverse events (CTCAE V5.0) and patient-reported outcomes of health-related quality of life are additional secondary endpoints.A total of 17 patients have completed sintilimab injection combination with concurrent chemoradiotherapy,17/53 (32%). Objective response rate (ORR) 62.5% and a median progression free survival (mPFS) 17 months. 1-year overall survival (OS) 88.2%. The most common AEs included granulocytopenia (43.7%), thrombo -cytopenia (56.2%), radiation esophagitis (50%), nausea and vomiting (50%), and immune pneumonia (18.7%). Of these AEs greater than grade 3 granulocytopenia (25.0%), thrombocytopenia (35.0%), radiation esophagitis (12.5%), and nausea and vomiting (31.3%), and one patient developed grade 3 immune pneumonia (6.2%), which recovered with treatment.The treatment of sintilimab with CCRT is safe and effective for localized ESCC patients, even with high-dose radiotherapy (60Gy). This study may help to address the unmet need for new therapeutic options for patients with localized ESCC." @default.
• W4387207967 created "2023-09-30" @default.
• W4387207967 creator A5003554962 @default.
• W4387207967 creator A5029837323 @default.
• W4387207967 date "2023-10-01" @default.
• W4387207967 modified "2023-10-17" @default.
• W4387207967 title "Sintilimab Injection Combination with Concurrent Chemoradiotherapy (cCRT) in Patients with Localized Esophageal Squamous Cell Carcinoma: A Prospective, Multi-Center, Single-Arm Trial in Progress" @default.
• W4387207967 doi "https://doi.org/10.1016/j.ijrobp.2023.06.2346" @default.
• W4387207967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785130" @default.
• W4387207967 hasPublicationYear "2023" @default.
• W4387207967 type Work @default.
• W4387207967 citedByCount "0" @default.
• W4387207967 crossrefType "journal-article" @default.
• W4387207967 hasAuthorship W4387207967A5003554962 @default.
• W4387207967 hasAuthorship W4387207967A5029837323 @default.
• W4387207967 hasConcept C120665830 @default.
• W4387207967 hasConcept C121332964 @default.
• W4387207967 hasConcept C121608353 @default.
• W4387207967 hasConcept C126322002 @default.
• W4387207967 hasConcept C141071460 @default.
• W4387207967 hasConcept C143998085 @default.
• W4387207967 hasConcept C188816634 @default.
• W4387207967 hasConcept C2776694085 @default.
• W4387207967 hasConcept C2778239845 @default.
• W4387207967 hasConcept C2778424827 @default.
• W4387207967 hasConcept C2779742542 @default.
• W4387207967 hasConcept C509974204 @default.
• W4387207967 hasConcept C61511704 @default.
• W4387207967 hasConcept C71924100 @default.
• W4387207967 hasConcept C90924648 @default.
• W4387207967 hasConceptScore W4387207967C120665830 @default.
• W4387207967 hasConceptScore W4387207967C121332964 @default.
• W4387207967 hasConceptScore W4387207967C121608353 @default.
• W4387207967 hasConceptScore W4387207967C126322002 @default.
• W4387207967 hasConceptScore W4387207967C141071460 @default.
• W4387207967 hasConceptScore W4387207967C143998085 @default.
• W4387207967 hasConceptScore W4387207967C188816634 @default.
• W4387207967 hasConceptScore W4387207967C2776694085 @default.
• W4387207967 hasConceptScore W4387207967C2778239845 @default.
• W4387207967 hasConceptScore W4387207967C2778424827 @default.
• W4387207967 hasConceptScore W4387207967C2779742542 @default.
• W4387207967 hasConceptScore W4387207967C509974204 @default.
• W4387207967 hasConceptScore W4387207967C61511704 @default.
• W4387207967 hasConceptScore W4387207967C71924100 @default.
• W4387207967 hasConceptScore W4387207967C90924648 @default.
• W4387207967 hasIssue "2" @default.
• W4387207967 hasLocation W43872079671 @default.
• W4387207967 hasLocation W43872079672 @default.
• W4387207967 hasOpenAccess W4387207967 @default.
• W4387207967 hasPrimaryLocation W43872079671 @default.
• W4387207967 hasRelatedWork W2249625608 @default.
• W4387207967 hasRelatedWork W2374149423 @default.
• W4387207967 hasRelatedWork W2375341503 @default.
• W4387207967 hasRelatedWork W2394853503 @default.
• W4387207967 hasRelatedWork W2404042595 @default.
• W4387207967 hasRelatedWork W2408650435 @default.
• W4387207967 hasRelatedWork W2411066725 @default.
• W4387207967 hasRelatedWork W2415196927 @default.
• W4387207967 hasRelatedWork W2418663701 @default.
• W4387207967 hasRelatedWork W363598932 @default.
• W4387207967 hasVolume "117" @default.
• W4387207967 isParatext "false" @default.
• W4387207967 isRetracted "false" @default.
• W4387207967 workType "article" @default.